IL17A and inflammatory bowel disease: The rest received mesalamine (3.2%), corticosteroids plus mesalamine (13%), corticosteroids plus TNF-α inhibitor (19.4%) and corticosteroids plus ustekinumab (3.2%).10 The occurrence of IBD has been reported in clinical trials of IL-17 inhibitors with varying incidence.